Why is Telix Pharmaceuticals stock sliding today?
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $TLX -4.09% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$TLX last traded at $9.15, -4.09% on the session. That puts it 30% shy of its 52-week high of $13.11 and 46% clear of its low of $6.28 — a little below the middle of the range. Over the year it has ranged 109% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $TLX page.
How much coverage it is getting
In the last 30 days Wook has filed 1 story about $TLX — 0 of them this week. None arrived this week, so the run has gone quiet. Across those stories the wording ran 100% bullish, 0% neutral and 0% bearish. This one reads neutral, so it sits in a small minority of the run. This is the only one from Investing.com; the rest came from other outlets. 12 of them are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
What to watch next
For the receipts, the $TLX page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $TLX is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $TLX. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 21, 2026. $TLX has moved -19.10% ($11.31 to $9.15). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.